Innovation Beyond Technology: Unilab
- First Online: 31 May 2018
Cite this chapter
- Jikyeong Kang 3 ,
- Maria Antonia OG Arroyo 3 ,
- John C Orlina 3 &
- Ariel T Lopez 3
836 Accesses
Making a mark in the global business community is a daunting task for any organization, especially when multinational companies (MNCs) have the resources to set market standards and define trends in industry innovation. This leaves local players in expansion limbo; once they implement innovation initiatives to “catch up” with MNC leaders, the market would have been flooded by similar offerings, leading to small-scale competition among laggards, while market leaders have already identified and are pursuing new trends.
Companies of all sizes should have innovation in mind, but it should not be pursued for its own sake. All innovation initiatives should result in making the firm measurably more competitive. Novel strategies and business models that have little to do with high-technology equipment or systems the big players use can prove to be just as successful (and more cost effective) in terms of scaling and expanding one’s business.
How does a business grow through innovation when it operates in a sector that has high barriers to entry, particularly in an innovation ecosystem that favors importing mature “turn-key” solutions that have been proven to work in the developed world? The pharmaceutical sector is one such area, heavily controlled by a few multinational players who have the resources to take big bets on multiple R&D projects and constantly churn out new products.
The sector is affected by both local and global forces because stringent government regulations vary from country to country while global advances in biomedical technology by large players make costs prohibitive. This forces smaller, local companies to pursue incremental innovation.
To succeed in this globalized economy, pharmaceutical companies must take advantage of other avenues for development, looking for different means of tapping the various areas and relationships within their value chain. One such example is United Laboratories Inc., a Philippine pharmaceutical company that has managed to grow itself from a small, local pharmaceutical supplier into a regional giant in South East Asia, in an industry that the country is not known for.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
- Available as EPUB and PDF
- Read on any device
- Instant download
- Own it forever
- Compact, lightweight edition
- Dispatched in 3 to 5 business days
- Free shipping worldwide - see info
- Durable hardcover edition
Tax calculation will be finalised at checkout
Purchases are for personal use only
Institutional subscriptions
Read more about Unilab here: http://www.unilab.com.ph/about/
Ochave, Atty. Jose Maria. 20 Apr. 2017. Senior Vice President for Growth Leadership – Unit 2; Chairman of the Board – Pharex Pharmaceuticals.
Engwa, Manuel P. 21 Jun. 2017. Corporate Senior Vice President, Office of the Chairman of the Board, Unilab (Philippines ) Inc.
Author information
Authors and affiliations.
Asian Institute of Management, Makati, Philippines
Jikyeong Kang, Maria Antonia OG Arroyo, John C Orlina & Ariel T Lopez
You can also search for this author in PubMed Google Scholar
Corresponding author
Correspondence to Jikyeong Kang .
Editor information
Editors and affiliations.
Instituto de Empresa, Madrid, Spain
Santiago Iñiguez de Onzoño
Graduate School of International Corporate Strategy, Hitotsubashi University, Tokyo, Japan
Kazuo Ichijo
Rights and permissions
Reprints and permissions
Copyright information
© 2018 The Author(s)
About this chapter
Kang, J., Arroyo, M.A.O., Orlina, J.C., Lopez, A.T. (2018). Innovation Beyond Technology: Unilab. In: Iñiguez de Onzoño, S., Ichijo, K. (eds) Business Despite Borders. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-319-76306-4_10
Download citation
DOI : https://doi.org/10.1007/978-3-319-76306-4_10
Published : 31 May 2018
Publisher Name : Palgrave Macmillan, Cham
Print ISBN : 978-3-319-76305-7
Online ISBN : 978-3-319-76306-4
eBook Packages : Business and Management Business and Management (R0)
Share this chapter
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
- Publish with us
Policies and ethics
- Find a journal
- Track your research
An official website of the United States government
Here’s how you know
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Take action
- Report an antitrust violation
- File adjudicative documents
- Find banned debt collectors
- View competition guidance
- Competition Matters Blog
New HSR thresholds and filing fees for 2024
View all Competition Matters Blog posts
We work to advance government policies that protect consumers and promote competition.
View Policy
Search or browse the Legal Library
Find legal resources and guidance to understand your business responsibilities and comply with the law.
Browse legal resources
- Find policy statements
- Submit a public comment
Vision and Priorities
Memo from Chair Lina M. Khan to commission staff and commissioners regarding the vision and priorities for the FTC.
Technology Blog
Best practices in building tech capacity in law enforcement agencies.
View all Technology Blog posts
Advice and Guidance
Learn more about your rights as a consumer and how to spot and avoid scams. Find the resources you need to understand how consumer protection law impacts your business.
- Report fraud
- Report identity theft
- Register for Do Not Call
- Sign up for consumer alerts
- Get Business Blog updates
- Get your free credit report
- Find refund cases
- Order bulk publications
- Consumer Advice
- Shopping and Donating
- Credit, Loans, and Debt
- Jobs and Making Money
- Unwanted Calls, Emails, and Texts
- Identity Theft and Online Security
- Business Guidance
- Advertising and Marketing
- Credit and Finance
- Privacy and Security
- By Industry
- For Small Businesses
- Browse Business Guidance Resources
- Business Blog
Servicemembers: Your tool for financial readiness
Visit militaryconsumer.gov
Get consumer protection basics, plain and simple
Visit consumer.gov
Learn how the FTC protects free enterprise and consumers
Visit Competition Counts
Looking for competition guidance?
- Competition Guidance
News and Events
Latest news, ftc to convene advisory group to fight scams against older adults april 2.
View News and Events
Upcoming Event
Ftc staff join naag consumer protection quarterly: no fooling: how to spot and avoid imposter scams.
View more Events
Sign up for the latest news
Follow us on social media
--> --> --> --> -->
Playing it Safe: Explore the FTC's Top Video Game Cases
Learn about the FTC's notable video game cases and what our agency is doing to keep the public safe.
Latest Data Visualization
FTC Refunds to Consumers
Explore refund statistics including where refunds were sent and the dollar amounts refunded with this visualization.
About the FTC
Our mission is protecting consumers and competition by preventing anticompetitive, deceptive, and unfair business practices through law enforcement, advocacy, and education without unduly burdening legitimate business activity.
Learn more about the FTC
Meet the Chair
Lina M. Khan was sworn in as Chair of the Federal Trade Commission on June 15, 2021.
Chair Lina M. Khan
Looking for legal documents or records? Search the Legal Library instead.
- Cases and Proceedings
- Premerger Notification Program
- Merger Review
- Anticompetitive Practices
- Competition and Consumer Protection Guidance Documents
- Warning Letters
- Consumer Sentinel Network
- Criminal Liaison Unit
- FTC Refund Programs
- Notices of Penalty Offenses
- Advocacy and Research
- Advisory Opinions
- Cooperation Agreements
- Federal Register Notices
- Public Comments
- Policy Statements
- International
- Military Consumer
- Consumer.gov
- Bulk Publications
- Data and Visualizations
- Stay Connected
- Commissioners and Staff
- Bureaus and Offices
- Budget and Strategy
- Office of Inspector General
- Careers at the FTC
Quest Diagnostics Inc.orporated and Unilab Corporation
- Competition
- Health Care
- Hospitals and Clinics
Case Summary
Quest Diagnostics settled FTC charges that its proposed acquisition of Unilab Corporation would substantially increase concentration in the clinical laboratory testing services market by agreeing to divest clinical laboratory testing assets in Northern California to Laboratory Corporation of America.
Case Timeline
File Decision and Order (Public Record Version) (45.45 KB)
PRESS RELEASE: Announced Action for April 8, 2003
Document Agreement Containing Consent Orders (13.59 KB)
Document Decision and Order [Public Record Version] (85.07 KB)
Document Order to Maintain Assets [Public Record Version] (71.4 KB)
Document Complaint (12.26 KB)
Document Analysis of Agreement Containing Consent Orders to Aid Public Comment (24.42 KB)
PRESS RELEASE: FTC to Require Divestiture as Condition of Clearing Quest Diagnostics, Inc.'s Acquisition of Unilab Corporation
IMAGES
VIDEO
COMMENTS
Fig. 10.1. Unilab’s innovation strategy: “building the better box”. Full size image. Early on, Unilab established a system of “tailored boxes” in their business units, allowing each unit to focus on competing with a particular foreign company’s brand and formulate their own respective strategies.
PRESS RELEASE: FTC to Require Divestiture as Condition of Clearing Quest Diagnostics, Inc.'s Acquisition of Unilab Corporation. Quest Diagnostics settled FTC charges that its proposed acquisition of Unilab Corporation would substantially increase concentration in the clinical laboratory testing services market by agreeing to divest clinical ...
Unilab_Case_Study-libre.pdf - Free download as PDF File (.pdf), Text File (.txt) or read online for free. The PHARMACEUTICAL INDUSTRY is highly regulated, capital intensive, and driven by large research and development expenditures. The revenues of drugs having patents that will expire from 2010 to 2014 are about $89. Billion USD. Patent cliff ...